Egalet Corp (EGLT) Files Form 4 Insider Selling : Stan Musial Sells 13,480 Shares

Egalet Corp (EGLT): Stan Musial , Chief Financial Officer of Egalet Corp sold 13,480 shares on Jul 1, 2016. The Insider selling transaction was reported by the company on Jul 6, 2016 to the Securities and Exchange Commission. The shares were sold at $5.05 per share for a total value of $68,174.00 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Jul 5, 2016, Jeffrey M. Dayno (Chief Medical Officer) sold 536 shares at $4.65 per share price.On Jul 5, 2016, Mark Strobeck (Chief Business Officer) sold 8,700 shares at $4.68 per share price.Also, On Apr 6, 2016, Robert S Radie (President and CEO) sold 5,000 shares at $6.99 per share price.On Apr 6, 2016, Deanne F. Melloy (Chief Commercial Officer) sold 860 shares at $6.96 per share price.

Shares of Egalet Corp (EGLT) ended Tuesday, Jul 6, 2016 session in red amid volatile trading. The shares closed down -0.17 points or -3.33% at $4.93 with 70,623 shares getting traded. Post opening the session at $5.11, the shares hit an intraday low of $4.83 and an intraday high of $5.14 and the price vacillated in this range throughout the day. The company has a market cap of $124 M and the number of outstanding shares has been calculated to be 2,50,85,554 shares. The 52-week high of Egalet Corp is $16.59 and the 52-week low is $4.34.

Egalet Corp Money Flow Index Chart

Egalet Corporation is a specialty pharmaceutical company developing manufacturing and commercializing medicines for patients with acute and chronic pain. The Company’s products include OXAYDO and SPRIX Nasal Spray. OXAYDO is the immediate-release oxycodone product formulated to deter abuse via snorting for the management of acute and chronic moderate to severe pain where an opioid is appropriate. SPRIX Nasal Spray is the nasal spray formulation of non-steroidal anti-inflammatory drug (NSAID) ketorolac used for short-term management of moderate to moderately severe pain that requires analgesia at the opioid level. The Company is developing two late-stage product candidates using Guardian Technology. The lead program Egalet-001 is an abuse-deterrent extended-release oral morphine formulation and Egalet-002 is an abuse-deterrent extended-release oral oxycodone formulation.

Leave a Reply

Egalet Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on Egalet Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.